192 related articles for article (PubMed ID: 10890271)
1. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: evidence from randomized, controlled trials in coronary heart disease and health economic evaluations.
Montagne O; Vedel I; Durand-Zaleski I
Clin Ther; 1999 Nov; 21(11):2027-35. PubMed ID: 10890271
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis, clinical trials, and transferability of research results into practice. The case of cholesterol-lowering interventions in the secondary prevention of coronary heart disease.
Marchioli R; Marfisi RM; Carinci F; Tognoni G
Arch Intern Med; 1996 Jun; 156(11):1158-72. PubMed ID: 8639010
[TBL] [Abstract][Full Text] [Related]
3. [Basic principles of cost-benefit analysis in long-term treatment of risk factors].
Szucs TD; Gutzwiller F
Schweiz Med Wochenschr; 1998 Dec; 128(49):1958-64. PubMed ID: 9887476
[TBL] [Abstract][Full Text] [Related]
4. Economic benefits of aggressive lipid lowering: a managed care perspective.
McKenney JM; Kinosian B
Am J Manag Care; 1998 Jan; 4(1):65-74. PubMed ID: 10179907
[TBL] [Abstract][Full Text] [Related]
5. [Current developments in prevention of coronary heart disease].
Windler E
Z Arztl Fortbild (Jena); 1996 Feb; 90(1):7-10. PubMed ID: 8650967
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of omega-3 fatty acids and the prevention of coronary heart disease.
Harper CR; Jacobson TA
Am J Cardiol; 2005 Dec; 96(11):1521-9. PubMed ID: 16310434
[TBL] [Abstract][Full Text] [Related]
7. Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials.
Briel M; Studer M; Glass TR; Bucher HC
Am J Med; 2004 Oct; 117(8):596-606. PubMed ID: 15465509
[TBL] [Abstract][Full Text] [Related]
8. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence.
Preiss D; Sattar N
Clin Endocrinol (Oxf); 2009 Jun; 70(6):815-28. PubMed ID: 19067719
[TBL] [Abstract][Full Text] [Related]
9. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
MacNeil P
Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolemia: design and baseline results of the Open Label Primary Care Study: Rosuvastatin Based Compliance Initiatives To Achievements of LDL Goals (ORBITAL) study.
Willich SN; Müller-Nordhorn J; Sonntag F; Völler H; Meyer-Sabellek W; Wegscheider K; Windler E; Katus H
Am Heart J; 2004 Dec; 148(6):1060-7. PubMed ID: 15632894
[TBL] [Abstract][Full Text] [Related]
11. Randomized clinical trials and recent patterns in the use of statins.
Wang TJ; Stafford RS; Ausiello JC; Chaisson CE
Am Heart J; 2001 Jun; 141(6):957-63. PubMed ID: 11376310
[TBL] [Abstract][Full Text] [Related]
12. Statins for primary and secondary prevention of coronary heart disease. A scientific review.
Carneiro AV; Costa J; Borges M
Rev Port Cardiol; 2004 Jan; 23(1):95-122. PubMed ID: 15058150
[TBL] [Abstract][Full Text] [Related]
13. [Benefits and costs of early detection and treatment of hypercholesterolemia].
Laaser U
Z Kardiol; 1994; 83 Suppl 6():163-7. PubMed ID: 7863690
[TBL] [Abstract][Full Text] [Related]
14. [Cholesterolemia control in Spain, 2000. A tool for cardiovascular disease prevention. Ministry of Health and Consumption, Spanish Society of Cardiology and Spanish Society of Arteriosclerosis].
Rev Esp Salud Publica; 2000; 74(3):215-53. PubMed ID: 10918811
[TBL] [Abstract][Full Text] [Related]
15. Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach.
Martikainen JA; Ottelin AM; Kiviniemi V; Gylling H
Eur J Cardiovasc Prev Rehabil; 2007 Apr; 14(2):265-72. PubMed ID: 17446806
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials.
Birjmohun RS; Hutten BA; Kastelein JJ; Stroes ES
J Am Coll Cardiol; 2005 Jan; 45(2):185-97. PubMed ID: 15653014
[TBL] [Abstract][Full Text] [Related]
17. [Effect of medicamentous cholesterol control on resources utilization in public health--significance of the Scandinavian Simvastatin Survival Study (4-S Study) for cost control in Swiss health management conditions].
Szucs TD; Lüscher TF; Gutzwiller F
Schweiz Med Wochenschr; 1997 Nov; 127(44):1819-23. PubMed ID: 9446200
[TBL] [Abstract][Full Text] [Related]
18. The pharmacoeconomic benefits of cholesterol reduction.
Gonzalez ER
Am J Manag Care; 1998 Feb; 4(2):223-30. PubMed ID: 10178493
[TBL] [Abstract][Full Text] [Related]
19. [Hypercholesterolemia and coronary disease: intervention strategies].
Brunelli C; Spallarossa P; Saccani A; Corsiglia L; Ghigliotti G; Caponnetto S
Cardiologia; 1991 Dec; 36(12 Suppl 1):303-8. PubMed ID: 1841785
[TBL] [Abstract][Full Text] [Related]
20. [Meta-analysis of therapeutic trials of primary prevention in ischemic cardiopathies by hypocholesteremic treatment].
Cucherat M; Boissel JP; Collet JP
Arch Mal Coeur Vaiss; 1992 Sep; 85 Spec No 2():105-8. PubMed ID: 1285686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
